Skip to main content
Erschienen in: Journal of Gastroenterology 8/2017

11.01.2017 | Original Article—Liver, Pancreas, and Biliary Tract

Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure

verfasst von: Keisuke Kakisaka, Kojiro Kataoka, Yuji Suzuki, Hidekatsu Kuroda, Yasuhiro Takikawa

Erschienen in: Journal of Gastroenterology | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Corticosteroid therapy has been commonly administered to patients with acute liver injury (ALI)/acute liver failure (ALF) in Japan to prevent the development of hepatic encephalopathy, but the appropriate timing to start corticosteroid therapy has not been determined and optimal response evaluation of the therapy has not been conducted. We prospectively investigated the optimal timing to start therapy on the established severity indication: the Japan Hepatic Encephalopathy Prediction Model (JHEPM) and prothrombin time (PT).

Methods

This prospective observational study enrolled 469 patients with ALI/ALF from 2004 to 2015. We evaluated 44 patients with ALF on high-dose corticosteroid therapy before hepatic coma development. The predictive performance for coma development was assessed using the receiver operator curve method in both PT and JHEPM probability the day before administering high-dose corticosteroid therapy.

Results

Among these patients, nine developed hepatic coma after the therapy. Selection bias was adjusted using propensity score method. High-dose corticosteroid therapy tended to decrease the risk of coma development although there was no statistical significance. The cut-off value of 53%, 1.95, and 39% in JHEPM probability, PT-international normalized ratio (PT-INR), and PT activity, respectively, showed high sensitivity and specificity.

Conclusions

We propose the appropriate timing to start high-dose corticosteroid therapy in patients with ALI/ALF; 40% of JHEPM probability, 1.53 of PT-INR, and 52% of PT because these values were theoretically discriminated at 98% coverage to the patients with coma. Because the study contained selection bias, the appropriate timing for therapy should be confirmed in a future prospective study.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–61.CrossRefPubMedPubMedCentral Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–61.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol. 2011;26(Suppl 1):65–71.CrossRefPubMed Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: a perspective from Japan. J Gastroenterol Hepatol. 2011;26(Suppl 1):65–71.CrossRefPubMed
3.
Zurück zum Zitat Yamashiki N, Sugawara Y, Tamura S, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl. 2012;18:1069–77.CrossRefPubMed Yamashiki N, Sugawara Y, Tamura S, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl. 2012;18:1069–77.CrossRefPubMed
4.
Zurück zum Zitat Ware AJ, Jones RE, Shorey JW, et al. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol. 1974;62:130–3.PubMed Ware AJ, Jones RE, Shorey JW, et al. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol. 1974;62:130–3.PubMed
5.
Zurück zum Zitat Gregory PB, Knauer CM, Kempson RL, et al. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med. 1976;294:681–7.CrossRefPubMed Gregory PB, Knauer CM, Kempson RL, et al. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med. 1976;294:681–7.CrossRefPubMed
6.
Zurück zum Zitat Redeker AG, Schweitzer IL, Yamahiro HS. Letter: Randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med. 1976;294:728–9.CrossRefPubMed Redeker AG, Schweitzer IL, Yamahiro HS. Letter: Randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med. 1976;294:728–9.CrossRefPubMed
7.
Zurück zum Zitat Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res. 2014;44:491–501.CrossRefPubMed Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res. 2014;44:491–501.CrossRefPubMed
8.
Zurück zum Zitat Ohira H, Takahashi A. Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan. Hepatol Res. 2012;42:131–8.CrossRefPubMed Ohira H, Takahashi A. Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan. Hepatol Res. 2012;42:131–8.CrossRefPubMed
9.
Zurück zum Zitat Kakisaka K, Kataoka K, Suzuki Y, et al. Necrotic cell death and suppression of T-cell immunity characterized acute liver failure due to drug-induced liver injury. Cytokine. 2016;86:21–8.CrossRefPubMed Kakisaka K, Kataoka K, Suzuki Y, et al. Necrotic cell death and suppression of T-cell immunity characterized acute liver failure due to drug-induced liver injury. Cytokine. 2016;86:21–8.CrossRefPubMed
10.
Zurück zum Zitat Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–90.CrossRefPubMed Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–90.CrossRefPubMed
11.
Zurück zum Zitat Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2–13.CrossRefPubMedPubMedCentral Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2–13.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology. 2014;59:612–21.CrossRefPubMed Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology. 2014;59:612–21.CrossRefPubMed
13.
Zurück zum Zitat Takikawa Y, Endo R, Suzuki K, et al. Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol. 2009;51:1021–9.CrossRefPubMed Takikawa Y, Endo R, Suzuki K, et al. Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol. 2009;51:1021–9.CrossRefPubMed
14.
Zurück zum Zitat Kakisaka K, Kataoka K, Onodera M, et al. Alpha-fetoprotein: a biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure. Hepatol Res. 2014;45:E12–20.CrossRefPubMed Kakisaka K, Kataoka K, Onodera M, et al. Alpha-fetoprotein: a biomarker for the recruitment of progenitor cells in the liver in patients with acute liver injury or failure. Hepatol Res. 2014;45:E12–20.CrossRefPubMed
15.
Zurück zum Zitat Kakisaka K, Kataoka K, Kuroda H, et al. Predictive formula for acute liver failure is useful for predicting the prognosis of patients with acute-on-chronic liver failure. Hepatol Res. 2016;46:459–67.CrossRefPubMed Kakisaka K, Kataoka K, Kuroda H, et al. Predictive formula for acute liver failure is useful for predicting the prognosis of patients with acute-on-chronic liver failure. Hepatol Res. 2016;46:459–67.CrossRefPubMed
16.
Zurück zum Zitat Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.CrossRefPubMed Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.CrossRefPubMed
17.
Zurück zum Zitat Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL). Gut. 1979;20:620–623. Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL). Gut. 1979;20:620–623.
19.
Zurück zum Zitat Takikawa Y, Harada M, Wang T, et al. Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease. Hepatol Res. 2014;44:92–101.CrossRefPubMed Takikawa Y, Harada M, Wang T, et al. Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease. Hepatol Res. 2014;44:92–101.CrossRefPubMed
20.
Zurück zum Zitat Kudo M, Todo A, Ikekubo K, et al. Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology. 1993;17:814–9.PubMed Kudo M, Todo A, Ikekubo K, et al. Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology. 1993;17:814–9.PubMed
21.
Zurück zum Zitat Kakisaka K, Kuroda H, Abe T, et al. Hepatic hemodynamics and elevation of liver stiffness as possible predictive markers of late-onset hepatic failure. Intern Med. 2016;55:1091–5.CrossRefPubMed Kakisaka K, Kuroda H, Abe T, et al. Hepatic hemodynamics and elevation of liver stiffness as possible predictive markers of late-onset hepatic failure. Intern Med. 2016;55:1091–5.CrossRefPubMed
Metadaten
Titel
Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure
verfasst von
Keisuke Kakisaka
Kojiro Kataoka
Yuji Suzuki
Hidekatsu Kuroda
Yasuhiro Takikawa
Publikationsdatum
11.01.2017
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 8/2017
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1306-5

Weitere Artikel der Ausgabe 8/2017

Journal of Gastroenterology 8/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.